Classification by type distinguishes the source and delivery format of astaxanthin, each influencing bioavailability, cost structure, and market positioning. Natural astaxanthin, extracted from the micro‑alga Haematococcus pluvialis, commands the largest share—approximately 55 %—due to consumer preference for bio‑identical antioxidants and the premium pricing it supports. Within this category, softgel and oil‑based liquid formulations dominate, offering enhanced lipid solubility that aligns with the carotenoid’s fat‑soluble nature. Synthetic astaxanthin, produced via chemical synthesis, accounts for roughly 25 % of volume; its lower production cost enables price‑sensitive segments, though regulatory scrutiny and perceived efficacy gaps limit its penetration in high‑end channels. Enhanced‑delivery types such as liposomal encapsulation and nanoparticle technologies represent emerging formats, together comprising about 15 % of the market; they aim to improve gastrointestinal absorption and target tissue distribution, attracting nutraceutical innovators. The remaining 5 % consists of powder and tablet formats designed for functional food fortification. By delineating these types, the market taxonomy clarifies investment priorities across manufacturing, formulation science, and distribution channels.
